Modified GLP-1 Peptides Resolving Half-Life and Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diabetes, obesity, and metabolic syndrome using GLP-1 are limited by the short half-life of GLP-1 peptides, leading to significant gastrointestinal side effects in some GLP-1 analogs developed to extend its duration.
Innovation Solution
Development of GLP-1 compounds with specific amino acid sequences and modifications, such as cyclic structures and pegylation, to enhance the half-life and reduce side effects, while maintaining insulinotropic activity and other GLP-1 activities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If GLP-1 analogs are developed to extend half-life, then duration of action is improved, but gastrointestinal side effects worsen
Solution Approach 1:
The patent applies parameter changes by systematically modifying amino acid residues at specific positions (7, 8, 22, 26, 33, 34, 36, 37) of the GLP-1 peptide sequence. These substitutions with conservative amino acids alter the molecular properties to extend half-life while reducing gastrointestinal side effects, resolving the technical contradiction between duration of action and side effect profile
Solution Approach 2:
The patent creates composite peptide structures by combining modified GLP-1 sequences with fatty acid amide groups at the N-terminus. This composite structure integrates the bioactive GLP-1 portion with a lipophilic anchor that enhances stability and half-life, while the specific modifications reduce gastrointestinal side effects
2Productivity
If GLP-1 analogs are developed to extend half-life, then productivity is improved, but reliability worsens due to side effects
Solution Approach 1:
By changing amino acid parameters at critical positions, the patent achieves both extended half-life for improved productivity and reduced gastrointestinal side effects for improved reliability, simultaneously addressing both requirements through precise molecular modification
Data Source
Figure 1
Figure 2A~2B
Figure 2C~2D
AI summary
GLP-1 compounds comprising GLP-1 analogs and methods of using the GLP-1 compounds for treating metabolic disorders, enhancing insulin expression, and promoting insulin secretion in a patient are provided.